PhaseBio

PhaseBio Pharmaceuticals and SFJ Pharmaceuticals Announce Approval of IND Application in China for Bentracimab

MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) this week announced that the Investigational New Drug (IND) application for bentracimab submitted to the Center for Drug Evaluation (CDE) of the …

PhaseBio Pharmaceuticals and SFJ Pharmaceuticals Announce Approval of IND Application in China for Bentracimab Read More